10 June 2024
10 June 2024
The sNDA approval is based on the findings from the Phase III study in more than 100 subjects in the US.
Artificial intelligence (AI) has the potential to revolutionize drug development through improved efficiency, accuracy, and speed.
The FDA’s decision is underpinned by positive results from a Phase III clinical trial.
The FDA is looking to ask questions about a change of primary endpoint, treatment cessation and mortality reporting from the donanemab trial.
The application is for the updated Spikevax vaccine that targets the JN.1 variant of the SARS-CoV-2 virus for the 2024 to 2025 season.
The prognostic factor(s) driving outcomes at the initial stages of hepatocellular carcinoma remain unclear, complicating the treatment choice.
In a Phase III trial, Alecensa showed a 76% decline in disease recurrence or mortality risk compared to chemotherapy.
There are currently only two FDA-approved treatments for the chronic lung disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
Give your business an edge with our leading industry insights.
